Sandoz has opened two new European facilities in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.
The inauguration of a new facility for the production of penicillin at Kundl, Austria, and a new biosimilar development center in Holzkirchen, Germany, reaffirm the dual Sandoz commitment to ensuring sustainable access to quality antibiotics and spearheading the development of biosimilars.
Sandoz has the only major remaining vertically integrated production network for penicillins in Europe; penicillins are the leading category of antibiotics worldwide. The EUR 150 million Kundl investment, which includes a contribution of EUR 50 million from the Austrian federal government, represents a significant upgrade of penicillin API (active pharmaceutical ingredient) manufacturing.
The EUR 25 million Holzkirchen investment will pave the way for the German site to become the leading Sandoz analytical characterization center for biosimilars.
The Austrian federal and Bavarian state governments have been highly supportive of these projects, recognizing their importance for ensuring the availability of medicines and advancing medical research in Europe.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!